Alvotech and jamp pharma announce receipt of marketing authorization for jamteki (avt04), the first biosimilar of stelara® (ustekinumab)

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and jamp pharma group (“jamp pharma”), a canadian owned pharmaceutical organization headquartered in the greater montreal area, announced today that health canada has granted jamp pharma marketing authorization for avt04, a biosimilar to stelara® (ustekinumab) developed by alvotech. avt04 will be marketed under the brand name jamtekitm.
ALVO Ratings Summary
ALVO Quant Ranking